Share this post:
Share this post:





RECOMMENDED
Israeli medical research is making another important step forward in the early identification of Alzheimer's disease.
An Israeli-developed artificial intelligence (AI) model has completed large-scale validation involving more than 1.6 million patient records from Israel and the United States. The technology is designed to identify people who may be at increased risk of developing Alzheimer's disease years before noticeable symptoms appear.
Developed by Israeli health-tech company ALZAI Health, the system analyzes information that already exists in patients' medical records, including routine blood test results, previous medical diagnoses and demographic information.
Unlike approaches that initially require expensive brain scans or invasive procedures, the technology can assess risk using information collected during ordinary medical care.
The research began at Clalit Health Services' Beilinson Hospital in Petah Tikva, in collaboration with Ariel University.
The research team examined hundreds of thousands of medical records and trained machine-learning models to identify patterns associated with future Alzheimer's risk.
Researchers discovered that certain indicators may already be present in routine medical records, even when individual results do not necessarily raise medical concerns. By analyzing multiple indicators together, the AI system can identify patterns that may point to an increased risk.
The technology was developed using existing medical information rather than requiring patients to undergo specialized testing at the initial assessment stage.
Alzheimer's is a progressive brain disease and the most common cause of dementia. It gradually affects memory, thinking and other cognitive abilities.
One of the biggest challenges is that the disease may develop 15–20 years before noticeable symptoms appear.
By the time memory problems and other cognitive difficulties become apparent, significant changes may already have occurred in the brain.
Early identification could give doctors an opportunity to monitor patients more closely and consider appropriate medical interventions. Some of the treatments available today are most effective during the early stages of the disease.
Dr. Amir Glik, Director of the Cognitive Neurology Service at Beilinson Hospital, initiated the research. He explained that identifying risk earlier could help address the challenge of patients seeking medical attention only after significant cognitive decline has already developed.
The research was conducted by Dr. Glik together with Professor Chen Hajjaj, Dr. Anat Goldstein and Dr. Orit Refaeli from Ariel University's Department of Industrial Engineering and Management.
The technology subsequently expanded beyond its original research setting, with validation involving more than 1.6 million medical records from Israel and the United States.
The research led to the establishment of ALZAI Health, through collaboration involving Mor Research Applications, Clalit's technology commercialization company, Ariel Scientific Innovation and the company's founders.
The company has also entered the international market, listing on the Toronto Stock Exchange's TSX Venture Exchange and raising approximately CAD $7.5 million.
According to the World Health Organization, approximately 60 million people worldwide live with dementia. Alzheimer's accounts for an estimated 60%–70% of cases.
The number of people living with dementia is projected to exceed 150 million by 2050, largely due to an aging global population.
Technology that can identify people at increased risk earlier could become an important tool for healthcare systems, medical research and future clinical trials.
An important distinction: The AI model assesses the risk of developing Alzheimer's disease. It does not independently diagnose the disease or establish that someone will develop it. Further medical evaluation remains essential.
The project is another example of Israeli medical innovation combining artificial intelligence, medical research and existing healthcare data to address a major global health challenge.
ABOUT US
SOCIAL NETWORKS
BE THE FIRST TO KNOW
FIND MORE
GET ONLINE